openPR Logo
Press release

Investigation announced for Long-Term Investors in NASDAQ: ACRS shares over possible Wrongdoing at Aclaris Therapeutics, Inc.

12-02-2019 06:52 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Aclaris Therapeutics, Inc. (NASDAQ: ACRS) shares.

An investigation on behalf of current long term investors in Aclaris Therapeutics, Inc. (NASDAQ: ACRS) shares.

An investigation was announced for long-term investors in shares of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) concerning potential breaches of fiduciary duties by certain directors of Aclaris Therapeutics, Inc..

Investors who are current long term investors in Aclaris Therapeutics, Inc. (NASDAQ: ACRS) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: ACRS stocks follows a lawsuit filed against Aclaris Therapeutics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: ACRS stocks, concerns whether certain Aclaris Therapeutics, directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that the Defendants failed to disclose to investors that the Company’s advertising materials minimized the risks and overstated the efficacy of ESKATA to generate sales, that, as a result, the Company was reasonably likely to face regulatory scrutiny, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in NASDAQ: ACRS shares over possible Wrongdoing at Aclaris Therapeutics, Inc. here

News-ID: 1874796 • Views: 165

More Releases from Shareholders Foundation

Lawsuit filed for Investors in Energy Transfer LP (NYSE: ET) over alleged Mislea …
An investor in Energy Transfer LP (NYSE: ET) filed a lawsuit over alleged violations of Federal Securities Laws by Energy Transfer LP in connection with certain allegedly false and misleading statements. Investors who purchased units of Energy Transfer LP (NYSE: ET) have certain options and for certain investors are short and strict deadlines running. Deadline: January 20, 2020. NYSE: ET investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
Investigation announced for Investors in shares of CBL & Associates Properties, …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at CBL & Associates Properties, Inc. Investors who purchased shares of CBL & Associates Properties, Inc (NYSE: CBL) and currently hold any of those NYSE: CBL shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain CBL & Associates Properties
Lawsuit filed for Investors in shares of Aurora Cannabis Inc. (NYSE: ACB)
The Shareholders Foundation announced that an investor, who purchased shares of Aurora Cannabis Inc. (NYSE: ACB), filed a lawsuit over alleged violations of Federal Securities Laws by Aurora Cannabis Inc. Investors who purchased shares of Aurora Cannabis Inc. (NYSE: ACB), have certain options and for certain investors are short and strict deadlines running. Deadline: January 21, 2020. NYSE: ACB investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779
Investigation announced for Long-Term Investors in shares of Verb Technology Com …
An investigation on behalf of current long-term investors in shares of Verb Technology Company, Inc. (NASDAQ: VERB) concerning potential breaches of fiduciary duties by certain directors and officers of Verb Technology Company, Inc. was announced. Investors who are current long term investors in Verb Technology Company, Inc. (NASDAQ: VERB) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a

All 5 Releases


More Releases for Aclaris

Alopecia Treatment Market Revenue Opportunies By Key Vendors: Histogen, Inc., Ac …
Alopecia also called as hair-loss or baldness is a medical condition that refers to loss of hairs from head or any part of the body. The condition can occur in both male and female and at any age. There are five major type of alopecia namely; alopecia areata, androgenic alopecia, ciatricial alopecia, traction alopecia, and alopecia totalis. Alopecia areata is a common autoimmune disorder in which the immune system of
Vitiligo Drug Market Analysis & Forecast 2019| Aclaris Therapeutics Inc, Arrien …
The research study presented here is a brilliant compilation of different types of analysis of critical aspects of the global Vitiligo Drug market. It sheds light on how the global Vitiligo Drug Market is expected to grow during the course of the forecast period. With SWOT analysis and Porter’s Five Forces analysis, it gives a deep explanation of the strengths and weaknesses of the global Vitiligo Drug market and different
Dermatology Drugs Market Key Player Analysis - Allergan Plc, Valeant Pharmaceuti …
Polaris Market Research presents a most up-to-date research on “Dermatology Drugs Market [(By Therapeutic Area (Atopic Dermatitis, Psoriasis, Acne, Rosacea), By Marketed Therapies (Biologics, Oral Drugs, Topical Drugs), By Approved Treatments (etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), ustekinumab (Stelara), secukinumab (Cosentyx), ixekizumab (Taltz), golimumab (Simponi), brodalumab (Siliq), and guselkamab (Tremfya), and By Region]: Market Size & Forecast, 2017 – 2022”. Polaris Market Research assumes that with the expected launch of the
Alopecia Treatment Market Revenue Opportunies By Key Vendors Histogen, Inc., Acl …
Global Alopecia Treatment Market, by Disease Type (Androgenic Alopecia, Alopecia Areata, Ciatricial Alopecia, Traction Alopecia, and Alopecia Totalis), by Drug Type (Vasodilators (Minoxidil), 5-Alpha Reductase Inhibitors (Finasteride), Corticosteroids, Immunosuppressants (Cyclosporine, and Others)), by Gender (Male and Female), by Route of Administration (Oral, Topical, and Injectable), by Distribution Channel (Hospital, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was
Dermatology Drugs Market to show significant growth| Key Players: Allergan Plc, …
Polaris Market Research assumes that with the expected launch of the potential promising therapies, the market is anticipated to expand in both psoriasis and atopic dermatitis segments. The Unites States accounts for the higher share of the market as compared to the Europe and Japan. The highest market size is due to the increased adoption of high priced biologics. Despite the launch and availability of multiple biologics, only 10% of
Seborrheic Keratosis Market 2018 | At a CAGR of 9.8% | by Aclaris Therapeutics, …
Seborrheic keratosis is one of the common noncancerous skin growths in older adults. The growths mostly appear on shoulders, back, abdomen, face, chest, and scalp. Cryosurgery is the most preferred method to remove the growth. The method uses liquid nitrogen to freeze off the growth. Notably, rising technological advancements and increasing participation of market leaders are the key factors driving the Seborrheic Keratosis Market. For instance, in December 2017, Aclaris Therapeutics